IXICO posts strong first-half growth and secures £10m to drive Tech Bio strategy

IXICO plc ( (GB:IXI) ) has issued an announcement.

IXICO plc, a neuroscience imaging and biomarker analytics company, reported another period of robust growth for the six months to 31 March 2026, with revenues expected to rise 23% to £3.9m and gross margin improving to 53%, driven by new contract wins, extensions and higher analysis volumes. The enlarged order book of £18.1m and a reduced EBITDA loss of £0.5m underline growing operational leverage, while a recently completed £10m capital raise is intended to accelerate its Tech Bio strategy to embed the IXI platform more deeply within CRO, clinical trial management and healthcare infrastructures, potentially strengthening its position in the neurology drug development ecosystem despite a lower cash balance ahead of the fundraise.

Spark’s Take on IXI Stock

According to Spark, TipRanks’ AI Analyst, IXI is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses and negative operating cash flow) and very bearish technicals (below key moving averages with negative MACD). A positive offset comes from supportive earnings-call guidance and order book growth, but valuation remains constrained by the company’s loss-making profile.

To see Spark’s full report on IXI stock, click here.

More about IXICO plc

IXICO plc is a neuroscience-focused imaging and biomarker analytics specialist that operates as an imaging contract research organisation, or iCRO, serving global pharmaceutical companies, biotechs, disease consortia and non-profits. Leveraging its proprietary AI-driven IXI platform and a worldwide network of imaging centres, the company supports clinical trials in neurological disorders such as Alzheimer’s, Huntington’s and Parkinson’s disease.

Average Trading Volume: 167,485

Technical Sentiment Signal: Sell

Current Market Cap: £6.83M

See more data about IXI stock on TipRanks’ Stock Analysis page.